Validation of Ion Chromatographic Methods

Applications of Ion Chromatography for Pharmaceutical and Biological Products

Volumn , Issue , 2012, Pages 285-308

  Karmarkar, Shreekant V ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

IC methods, validation; Reversed phase HPLC; Validation approaches and IC

Indexed keywords

EID: 84886047257     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118147009.ch15     Document Type: Chapter

References (40)

1. United States Pharmacopeial Convention. General Chapter: <1225>, Validation of Compendial Procedures, 2009. USP 32-NF 27, Rockville, Maryland.
2. United States Pharmacopeial Convention. Pharmacopeial Forum, In-Process Revision to General Chapter: <1086>, Impurities in Official Articles. USP-PF 35(5), 2009, Rockville, Maryland.
3. FDA-CDER, Guidelines for submitting samples and analytical data for methods validation, February 1987.
4. FDA-CDER, Reviewer guidance: Validation of chromatographic methods-CDER guidance document, November 1994.
5. ICH Harmonised Tripartite Guideline, Q1A (R2), Stability testing of new drug substances and products, 2003.
6. ICH Harmonised Tripartite Guideline ICH Q1B, Stability testing: Photostability testing of new drug substances and drug products, 1996.
7. ICH Harmonised Tripartite Guideline ICH Q2(R1), Validation of analytical procedures: Text and methodology, 2005.
8. ICH Harmonised Tripartite Guideline ICH Q3A(R2), Impurities in new drug substances, 2006.
9. ICH Harmonised Tripartite Guideline ICH Q3B(R2), Impurities in new drug products, 2006.
10. ICH Harmonised Tripartite Guideline ICH Q5C, Quality of biotechnology products: Stability testing of biotechnological/biological products, 1995.
11. ICH Harmonised Tripartite Guideline ICH Q5E, Comparability of biotechnological/ biological products subjected to changes in their manufacturing process, 2004.
12. ICH Harmonised Tripartite Guideline ICH Q6A, Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances, 1999.
13. Reynolds D, Facchine K, Mullaney J, Alsante K, Hatajik T, Motto M. Available guidance and best practices for conducting forced degradation studies. Pharmaceutical Technology 2002; February: 48-56.
14. Karmarkar S, Miller R, Yang X, and Garber R. Design of Forced Degradation Experiments to Demonstrate Specificity of Stability Indicating Methods for Pharmaceutical Injection Products, Presented at the LC-GC's PharmSep, Symposium for Separation Scientists in Pharmaceuticals, Philadelphia, September 21-22, 2009.
15. Dionex Corporation. Technical Note 48: Determination of trace anions in high-purity water by high-volume direct injection with the EG40.
16. Dionex Corporation. Technical Note 71: Eluent preparation for high-performance-anionexchange chromatography with pulsed amperometric detection.
17. Dionex Corporation. Technical Note 63: Peak identification and estimation of percent purity using HPAE with 3-D Amperometry.
18. Tsai EW, Ip DP, Brooks MA. Determination of alendronate in pharmaceutical dosage formulations by ion chromatography with conductivity detection. J. Chromatogr. 1992;596:217-224.
19. Tsai EW, Chamberlin SD, Forsyth RJ, Bell C, Ip DP, Brooks MA. Determination of biphosphonate drugs in pharmaceutical dosage formulations by ion chromatography with indirect UV detection. J. Pharm. Biomed. Anal. 1994;12:983-991.
20. Kosonen JP. Determination of disodium clodronate in bulk material and pharmaceuticals by ion chromatography with post-column derivatization. J. Pharm. Biomed. Anal. 1992;10:881-887.
21. Karmarkar S, Koberda M, Momani J, Kotecki D, Garber R. Validated ion exclusion chromatographic method for citrate and acetate in medical fluid. J. Chromatogr. A 2004;1039:147-153.
22. Lord BS, Stringham RW. Liquid chromatographic determination of organic acids used as pharmaceutical counterions. Anal. Chem. 1996;68:1067-1070.
23. Annable PL. Determination of alkyl sulfonic acids in pharmaceuticals by ion chromatography. J. Chromatogr. A. 1996;724:199-206.
24. Warnock M, Nair L, Sadain S, Jenke DR. Evaluation of an ion exclusion/direct conductivity method for quantitating acetic and lactic acids in pharmaceutical LVP base formulations. J. Liq. Chromatogr. & Rel. Technol. 2002;25:541-560.
25. Nair JB. Determination of trace levels of cyanamide in a novel potassium channel activator bulk drug by pulsed electrochemical detection. J. Chromatogr. A. 1994;671:367-374.
26. Jagota NK, Nair JB, Kurtulik PT. Ion chromatography of methansulfonic acid in pharmaceuticals. J. Pharm. Biomed. Anal. 1995;13:1291-1295.
27. Yang L, Liu L, Olsen BA, Nussbaum MA. The determination of oxalic acid, oxamic acid and oxamide in a drug substance by ion exclusion chromatography. J. Biomed. Pharm. Anal. 2000;22:487-493.
28. Micheel AP, Ko CY, Guh HY. Ion chromatography method and validation for the determination of sulfate and sulfamate ions in topiramate drug substance and finished product. J. Chromatogr. A. 1998;709:166-172.
29. Prasanna JS, Sharma H K, Mukkanti K, Sivakumaran M, Pavan Kumar KSR, Jagadesh Kumar V. Validation of a sensitive ion chromatography method for determination of monoethylsulfate in Indinavir sulfate drug substance. J. Pharm. Biomed. Anal. 2009;50:1065-1069.
30. Chen Z, Darvell B, Leung V. Validation of ion chromatography for human salivary anionic analysis. Archives of Oral Biology, 2004;49:855-862.
31. Robinett RSR, George HA, Herber WK. Determination of inorganic cations in fermentation and cell culture media using cation-exchange liquid chromatography and conductivity detection. J. Chromatogr. A. 1995;718:319-327.
32. Fernando PN, Egwu IN, Hussain MS. Ion chromatographic determination of trace hydroxylamine in waste streams generated by a pharmaceutical reaction process. J. Chromatogr. A. 2002;956:261-270.
33. Samy R, Faustino P, Adams W, Yu L, Khan M, Yang Y. Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate. J. Pharm. Biomedical Anal. 2010;51:1108-1112.
34. Waterworth JP. Validation of ion chromatographic methods for the trace analysis of ions in pharmacopeial grades of water. J. Chromatogr. A. 1997;770:99-104.
35. Moore E. Heparin impurities testing, 3rd workshop on the characterization of Heparin products,, Rockville, Maryland: US Pharmacopeial Convention; July 27-28, 2009.
36. USP-PF IRA, USP32-NF27. Heparin Sodium, 2009. Rockville, Maryland: US Pharmacopeial Convention; 2009.
37. Dionex Corporation. Application Note 199: Determination of N-methylpyrrolidine in Cefepime using a reagent-free ion chromatography system.
38. Dionex Corporation. Application Note 186: Analysis of paromomycin by HPAE-PAD.
39. DeBorba BM, Rohrer JS, Bhattacharyya L. Development and validation of an assay for citric acid/citrate and phosphate in pharmaceutical dosage forms using ion chromatography with suppressed conductivity detection. J. Pharmaceutical Biomedical Anal. 2004;36:517-524.
40. Jenke D, Sadain S, Nunez K, Byrne F. Performance characteristics of an ion chromatographic method for the quantitation of citrate and phosphate in pharmaceutical solutions. J. Chromatogr. Sci. 2007;45:50-56.